UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

Cancer treatment reviews, 2015-02, Vol.41 (2), p.114-121

2015

Volltextzugriff (PDF)

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1192-1193

2021

Volltextzugriff (PDF)

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

Cancer treatment reviews, 2021-11, Vol.100, p.102295-102295, Article 102295

2021

Volltextzugriff (PDF)

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Annals of oncology, 2022-11, Vol.33 (11), p.1179-1185

2022

Volltextzugriff (PDF)

Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials

Urologic oncology, 2020-10, Vol.38 (10), p.798.e17-798.e24

2020

Volltextzugriff (PDF)

New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors

Expert opinion on drug metabolism & toxicology, 2016-01, Vol.12 (1), p.57-75

2016

Volltextzugriff (PDF)

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

ESMO open, 2023-04, Vol.8 (2), p.101154, Article 101154

2023

Volltextzugriff (PDF)

Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi18

2017

Volltextzugriff (PDF)

1592P Cardiovascular toxicity in patients treated with a PARP inhibitor for solid tumors: A meta-analysis

Annals of oncology, 2022-09, Vol.33, p.S1273

2022

Volltextzugriff (PDF)

Assessing predictive factors for Disease-Free Survival (DFS) and Overall Survival (OS) in patients eligible for adjuvant immunotherapy (IO) following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC)

European urology, 2024-03, Vol.85, p.S320

2024

Volltextzugriff (PDF)

P231 - Assessing predictive factors for Disease-Free Survival (DFS) and Overall Survival (OS) in patients eligible for adjuvant immunotherapy (IO) following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC)

European urology, 2024-03, Vol.85, p.S320-S320

2024

Volltextzugriff (PDF)

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

Annals of oncology, 2024-09, Vol.35, p.S1264-S1264

2024

Volltextzugriff (PDF)

1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

Annals of oncology, 2023-10, Vol.34, p.S1013-S1013

2023

Volltextzugriff (PDF)

P225 - Efficacy and safety of the combination of cisplatin plus Nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial)

European urology, 2024-03, Vol.85, p.S313-S313

2024

Volltextzugriff (PDF)

Efficacy and safety of the combination of cisplatin plus Nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial)

European urology, 2024-03, Vol.85, p.S313

2024

Volltextzugriff (PDF)

A1033 - Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study

European urology, 2023-02, Vol.83, p.S1490-S1491

2023

Volltextzugriff (PDF)

Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study

European urology, 2023-02, Vol.83, p.S1490-S1491

2023

Volltextzugriff (PDF)

First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

European urology, 2022-02, Vol.81, p.S1335-S1336

2022

Volltextzugriff (PDF)

Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2016-09, Vol.27, p.iv34

2016

Volltextzugriff (PDF)

The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors

Annals of oncology, 2016-09, Vol.27, p.iv89

2016

Volltextzugriff (PDF)

Adjuvant immunotherapy bladder score (AIOB): a new score to identify the ideal candidate for adjuvant (adj) immunotherapy (IO) in patients (pts) undergoing radical cystectomy (RC) for muscle invasive bladder cancer (MIBC)

European urology open science (Online), 2023-11, Vol.57, p.S344

2023

Volltextzugriff (PDF)

P253 - Adjuvant immunotherapy bladder score (AIOB): a new score to identify the ideal candidate for adjuvant (adj) immunotherapy (IO) in patients (pts) undergoing radical cystectomy (RC) for muscle invasive bladder cancer (MIBC)

European urology open science (Online), 2023-11, Vol.57, p.S344-S344

2023

Volltextzugriff (PDF)

De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification

Annals of oncology, 2015-10, Vol.26, p.vi63

2015

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(151)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials

New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies

1592P Cardiovascular toxicity in patients treated with a PARP inhibitor for solid tumors: A meta-analysis

Assessing predictive factors for Disease-Free Survival (DFS) and Overall Survival (OS) in patients eligible for adjuvant immunotherapy (IO) following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC)

P231 - Assessing predictive factors for Disease-Free Survival (DFS) and Overall Survival (OS) in patients eligible for adjuvant immunotherapy (IO) following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC)

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

P225 - Efficacy and safety of the combination of cisplatin plus Nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial)

Efficacy and safety of the combination of cisplatin plus Nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial)

A1033 - Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study

Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study

Mismatch between clinical and pathological T stage among patients with suspected renal cell carcinoma undergoing surgery: Potential implications for target volume delineation and Stereotactic Body Radiotherapy (SBRT) implementation for localized renal masses

P135 - Mismatch between clinical and pathological T stage among patients with suspected renal cell carcinoma undergoing surgery: Potential implications for target volume delineation and Stereotactic Body Radiotherapy (SBRT) implementation for localized renal masses

First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC)

The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors

Adjuvant immunotherapy bladder score (AIOB): a new score to identify the ideal candidate for adjuvant (adj) immunotherapy (IO) in patients (pts) undergoing radical cystectomy (RC) for muscle invasive bladder cancer (MIBC)

P253 - Adjuvant immunotherapy bladder score (AIOB): a new score to identify the ideal candidate for adjuvant (adj) immunotherapy (IO) in patients (pts) undergoing radical cystectomy (RC) for muscle invasive bladder cancer (MIBC)

De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification

Suchergebnisse filtern